
Opinion|Videos|July 1, 2024
Treatments Approved for Treatment of Spinal Muscular Atrophy
Key opinion leaders (KOLs) examine the mechanisms of action and other pertinent information regarding FDA-approved treatments for spinal muscular atrophy (SMA), sharing their perspectives on these therapies with a particular focus on the various modes of administration.
Advertisement
Episodes in this series

- Please review mechanism of action and other details for treatments that are FDA approved for SMA.
- Nusinersen, Onasemnogene abeparvovec, Risdiplam
- Based on the pathophysiology of SMA, do you expect mechanism of action to impact disease pathology differently?
How do you feel about mode of administration?
How do you discuss the progressive nature of SMA with your adult patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Hidden Burden of Living With Epilepsy
2
FDA Approves Zilganersen, First Treatment for Alexander Disease
3
American Academy of Neurology, American Headache Society Issue Updated Guideline on Migraine Prevention
4
uniQure Submits BLA for Gene Therapy in Huntington Disease
5

















